読み込み中
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
通常取引
$11.30
−$0.39 · -3.34%
日中の時刻はETです。市場データは遅延する場合があります。
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
日中レンジ
現在 $11.30
52週レンジ
現在 $11.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
59
まちまち
リスク
52
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
日中レンジ
現在 $11.30
52週レンジ
現在 $11.30
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 62.2万 USD | 59.6万 USD | 53.7万 USD | 46.6万 USD | — |
| 粗利益 | −62.2万 USD | −59.6万 USD | −53.7万 USD | −46.6万 USD | — |
| 研究開発 | 5912.9万 USD | 4435万 USD | 5706.3万 USD | 4861.3万 USD | 2477.8万 USD |
| 販売・一般管理 | 2033.8万 USD | 1803.3万 USD | 2112.7万 USD | 1898万 USD | 1105.3万 USD |
| 営業費用 | 7884.5万 USD | 6178.7万 USD | 7765.3万 USD | 6712.7万 USD | 3583.1万 USD |
| 受取利息 | 967.5万 USD | 1279.5万 USD | — | — | — |
| 減価償却費と償却費 | 62.2万 USD | 59.6万 USD | 53.7万 USD | 40.6万 USD | 12.9万 USD |
| 営業利益 | −7946.7万 USD | −6238.3万 USD | −7819万 USD | −6759.3万 USD | −3583.1万 USD |
| 純利益 | −6979.2万 USD | −4958.8万 USD | −6686.2万 USD | −6330.8万 USD | −3553.3万 USD |
会社概要が更新されました 2026年10月8日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$22.33
上昇余地（97.61%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1752.06万0.00%2.3兆 USD0.03%$379.19-0.48%
State Street SPDR S&P Biotech ETFXBI1122.9万0.11%100.75億 USD0.35%$148.26-1.31%
iShares Russell 2000 ETFIWM972.86万0.01%785.63億 USD0.19%$277.03-0.24%
Vanguard Extended Market ETFVXF571.07万0.01%954億 USD0.05%$232.35-0.49%
Dimensional - US Small Cap ETFDFAS352.89万0.01%336.6億 USD0.31%$77.955+0.04%
iShares Russell 2000 Growth ETFIWO340.86万0.02%142.49億 USD0.24%$352.73-0.74%
iShares Biotechnology ETFIBB305.23万0.03%104.01億 USD0.44%$199.22-2.03%
Fidelity Enhanced Small Cap ETFFESM293.85万0.04%64.1億 USD0.28%$45.12-0.22%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
